A growing body of evidence demonstrates that epigenetic changes have a tremendous impact on cancer development and progression.1,2
Epigenomic insights, specifically methylation sequencing, can advance multiple precision
oncology applications.
IDENTIFY MORE PATIENTS
Dramatically improve sensitivity in MRD and monitoring & potentially identify up to 50% more cancer patients.3-5*
MRD, minimal residual disease
*Compared with genomic-only detection.
PREDICT TREATMENT RESPONSE WITH MORE ACCURACY
Potentially identify subsets of patients eligible for specific therapies, predict response to therapy and survival probability.6-8
STRATIFY PATIENTS AND CANCERS
Discriminate between cancer subtypes, allowing for more precise treatment selection.8
Home Oncology Portfolio Partnerships European Policy Guardant Infinity™ for BioPharma